Clinical Trial Update: Gadofosveset Trisodium (Ablavar, Gdfos) in Distinguishing Hemangiomas and Metastases: A Prospective Trial [NA]

View source ↗

Summary

A trial evaluating gadofosveset trisodium (Ablavar) to help distinguish liver hemangiomas from metastases using MRI; status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Hemangioma
• Liver Metastases
• Liver Neoplasms

Drugs mentioned

• Ablavar (gadofosveset trisodium)

Snippet

Sponsor: Sunnybrook Health Sciences Centre | Conditions: Cancer, Metastases | NA | Status: UNKNOWN